Inicio>>Signaling Pathways>> Ubiquitination/ Proteasome>> Autophagy>>Sunitinib

Sunitinib

Catalog No.GC17651

Sunitinib (SU 11248) es un inhibidor de la tirosina quinasa del receptor de objetivos mÚltiples con IC50 de 80 nM y 2 nM para VEGFR2 y PDGFRβ, respectivamente. Sunitinib, un inhibidor competitivo de ATP, inhibe eficazmente la autofosforilaciÓn de Ire1α al inhibir la autofosforilaciÓn y la consiguiente activaciÓn de la RNasa.

Products are for research use only. Not for human use. We do not sell to patients.

Sunitinib Chemical Structure

Cas No.: 557795-19-4

Tamaño Precio Disponibilidad Cantidad
10mM (in 1mL DMSO)
40,00 $
Disponible
100mg
36,00 $
Disponible
500mg
71,00 $
Disponible
1g
113,00 $
Disponible
2g
155,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com

Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents Related Products

Sunitinib is an oral, multi-targeted and small-molecule inhibitor of receptor tyrosine kinase (RTK) [1].

Sunitinib is a RTK inhibitor against vascular endothelial growth factor receptors (VEGFR1-3), platelet-derived growth factor receptors (PDGFRα and PDGFRβ ), stem cell factor receptor (c-kit), glial cell-line derived neurotrophic factor receptor(RET). Sunitinib has been reported to inhibit the growth in five NPC cell lines (HK1, CNE-2, HON E-1, CNE-1 and C666-1) with the IC50 values of 2.06 ± 0.29μM, 3.45 ± 0.11μM, 4.07 ± 1.07μM, 2.60 ± 0.38 and 7.57 ± 1.74μM, respectively. Apart from these, Sunitinib has been observed to induce apoptosis in NPC cells as well as induce cell cycle arrest at the G0 /G1 phase in HONE-1 and CNE-2 cells. In vivo, Sunitinib treatment could induce a significant reduction in MVD in CNE2 NPC xenograft [1].

References:
[1]Hui EP1, Lui VW, Wong CS, Ma BB, Lau CP, Cheung CS, Ho K, Cheng SH, Ng MH, Chan AT. Preclinical evaluation of sunitinib as single agent or in combination with chemotherapy in nasopharyngeal carcinoma. Invest New Drugs. 2011 Dec;29(6):1123-31.

Reseñas

Review for Sunitinib

Average Rating: 5 ★★★★★ (Based on Reviews and 19 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Sunitinib

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.